Influence of IGFBP3 Gene Polymorphisms on IGFBP3 Serum Levels and the Risk of Prostate Cancer in Low-risk Korean Men

Urology

Volumn 75, Issue 6, 2010, Pages 1516.e1-1516.e7

  Park, Kwanjin ^a   Kim, Jeong H ^b   Jeon, Hwang G ^a   Byun, Seok S ^c   Lee, Eunsik ^a  

^a Seoul National University   (South Korea)

^b Kangwon National University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3;

ADULT; AGED; ARTICLE; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77952744178     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.08.023     Document Type: Article

References (34)

1. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80 (1999) 827-841
2. Stanford J.L., Stephenson R.A., Coyle L.M., et al. Prostate Cancer Trends, 1973-1995; SEER Program (1999), National Cancer Institute, Bethesda, MD NIH Pub. No. 99-4543
3. Shimizu H., Ross R.K., Bernstein L., et al. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles county. Br J Cancer 63 (1991) 963-966
4. Lee J., Demissie K., Lu S.E., et al. Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control 14 (2007) 78-85
5. Page W.F., Braun M.M., Partin A.W., et al. Heredity and prostate cancer: a study of World War II veteran twins. Prostate 33 (1997) 240-245
6. Schaid D.J., McDonnell S.K., Blute M.L., et al. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 62 (1998) 1425-1438
7. Verhage B.A., Baffoe-Bonnie A.B., Baglietto L., et al. Autosomal dominant inheritance of prostate cancer: a confirmatory study. Urology 57 (2001) 97-101
8. Silha J.V., Sheppard P.C., Mishra S., et al. Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. Endocrinology 147 (2006) 2112-2121
9. Liu B., Lee K.W., Anzo M., et al. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 26 (2007) 1811-1819
10. Harrela M., Koistinen H., Kaprio J., et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-1, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 98 (1996) 2612-2615
11. Kao P.C., Matheny A.P.J., and Lang C.A. Insulin-like growth factor-I comparisons in healthy twin children. J Clin Endocrinol Metab 78 (1994) 310-312
12. Chan J.M., Stampfer M.J., Giovannucci E., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 (1998) 563-566
13. Stattin P., Bylund A., Rinaldi S., et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92 (2000) 1910-1917
14. Harman S.M., Metter E.J., Blackman M.R., et al. Baltimore Longitudinal Study on aging. Serum levels of insulin-like growth factor I (IGF-1), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 85 (2000) 4258-4265
15. Wolk A., Mantzoros C.S., Andersson S.O., et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90 (1998) 911-915
16. Severi G., Morris H.A., MacInnis R.J., et al. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15 (2006) 1137-1141
17. Chen C., Lewis S.K., Voigt L., et al. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 103 (2005) 76-84
18. Chokkalingam A.P., Pollak M., Fillmore C.M., et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers. Prev 10 (2001) 421-427
19. Hernandez W., Grenade C., Santos E.R., et al. IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis 28 (2007) 2154-2159
20. Deal C., Ma J., Wilkin F., et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86 (2001) 1274-1280
21. Wang L., Habuchi T., Tsuchiya N., et al. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res 63 (2003) 4407-4411
22. Moon J.W., Chang Y.S., Ahn C.W., et al. Promoter -202 A/C polymorphism of insulin-like growth factor binding protein-3 gene and non-small cell lung cancer risk. Int J Cancer 118 (2006) 353-356
23. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
24. Platz E.A., Pollak M.N., Rimm E.B., et al. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 8 (1999) 1107-1110
25. Tricoli J.V., Winter D.L., Hanlon A.L., et al. Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer. Urology 54 (1999) 178-182
26. DeLellis K., Rinaldi S., Kaaks R.J., et al. Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-1) and IGF binding protein-3 (IGFBP-3): the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 13 (2004) 1444-1451
27. Li L., Cicek M.S., Casey G., et al. No association between genetic polymorphisms in insulin and insulin receptor substrate-1 and prostate cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 2462-2463
28. Schildkraut J.M., Demark-Wahnefried W., Wenham R.M., et al. IGF1 (CA)19 repeat and IGFBP3 -202 A/C genotypes and the risk of prostate cancer in Black and White men. Cancer Epidemiol Biomarkers Prev 14 (2005) 403-408
29. Chen C., Freeman R., Voigt L.F., et al. Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor. Cancer Epidemiol Biomarkers Prev 15 (2006) 2461-2466
30. Baxter R.C. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 54 (2001) 145-148
31. Qin L.Q., Xu J.Y., Wang P.Y., et al. Milk consumption is a risk factor for prostate cancer in Western countries: evidence from cohort studies. Asia Pac J Clin Nutr 16 (2007) 467-476
32. Gunnell D., Oliver S.E., Peters T.J., et al. Are diet-prostate cancer associations mediated by the IGF axis?. A cross-sectional analysis of diet, IGF-1 and IGFBP-3 in healthy middle-aged men. Br J Cancer 88 (2003) 1682-1686
33. Peng L., Malloy P.J., and Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 18 (2004) 1109-1119
34. Raimondi S., Johanson H., Maisonneuve P., et al. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 30 (2009) 1170-1180